stockrowRevvity Inc.
RVTY Healthcare Diagnostics & Research
Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024.
- Revenue
- +4.29%
- EPS
- +2.17%
- Free cash flow
- +27.0%
- Total debt
- −18.1%
Quarter to September 2026, against a year earlier
Follow RVTY
Alert me
Revvity Inc. (RVTY) EPS (diluted)
Revvity Inc.'s EPS (diluted) for fiscal 2025 was $2.07, down 5.91% from $2.20 in fiscal 2024. Over the twelve months to 30 September 2026 it was $2.26. Over the past ten years it has ranged from $1.87 (fiscal 2015) to $7.99 (fiscal 2021); the current reading is higher than 27% of that period. Revvity Inc. ranks 15th of 49 Diagnostics & Research companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $2.07 | (5.91%) |
| FY2024 | $2.20 | (60.36%) |
| FY2023 | $5.55 | 21.18% |
| FY2022 | $4.58 | (42.68%) |
| FY2021 | $7.99 | 23.11% |
| FY2020 | $6.49 | 218.14% |
| FY2019 | $2.04 | (4.23%) |
| FY2018 | $2.13 | (19.32%) |
| FY2017 | $2.64 | 24.53% |
| FY2016 | $2.12 | 13.37% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.56 | 18.53% |
| Jun 2026 | $0.47 | 30.56% |
| Mar 2026 | $0.36 | (58.62%) |
| Dec 2025 | $0.87 | 117.50% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| MEDP Medpace Holdings, Inc. compare | $18.04 |
| LH Labcorp Holdings Inc. compare | $12.19 |
| DGX Quest Diagnostics Incorporated compare | $10.04 |
| ILMN Illumina, Inc. compare | $5.81 |
| ICLR ICON PLC compare | $5.81 |
| RVTY Revvity Inc. | $2.26 |
| QGEN QIAGEN N.V. compare | $1.95 |
| CRL Charles River Laboratories International, Inc. compare | $0.93 |
| GH Guardant Health, Inc. compare | −$3.68 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on RVTY
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement